Evidence map›Paper›PMID 40841654›Full record

ArticleAIDS research and therapy2025

Factors associated with interrupted pre-exposure prophylaxis (PrEP) in a Brazilian cohort: a brief communication.

Patricia Matias Pinheiro, Nathalia Pedrosa Lima, Angelica Espinosa Miranda, Valbert Oliveira Costa Filho, Igor Pacheco Fiuza Romeiro, Hermano Alexandre Lima Rocha, Wildo Navegantes de Araújo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patricia Matias PinheiroGraduate Program in Tropical Medicine, School of Medicine, University of Brasília, Distrito Federal, Brasília, Brazil.ORCID 0000-0002-0167-4782
Nathalia Pedrosa LimaGraduate Program in Tropical Medicine, School of Medicine, University of Brasília, Distrito Federal, Brasília, Brazil.ORCID 0000-0002-5945-7297
Angelica Espinosa MirandaPostgraduate Program in Infectious Diseases, Health Sciences Center, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil.ORCID 0000-0002-5556-8379
Valbert Oliveira Costa FilhoDepartment of Community Health, Federal University of Ceará, Rua Papi Júnior, 1223, 5th. Floor, Fortaleza, Ceará, Brazil.ORCID 0009-0003-2864-0966
Igor Pacheco Fiuza RomeiroDepartment of Community Health, Federal University of Ceará, Rua Papi Júnior, 1223, 5th. Floor, Fortaleza, Ceará, Brazil.ORCID 0000-0001-8555-179X
Hermano Alexandre Lima RochaDepartment of Community Health, Federal University of Ceará, Rua Papi Júnior, 1223, 5th. Floor, Fortaleza, Ceará, Brazil. hermano@ufc.br.ORCID 0000-0001-9096-0969
Wildo Navegantes de AraújoGraduate Program in Tropical Medicine, School of Medicine, University of Brasília, Distrito Federal, Brasília, Brazil.ORCID 0000-0002-6856-4094

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo analyze factors associated with the discontinuation of pre-exposure prophylaxis (PrEP) for HIV among users in Brazil.

methodsAn analytical case-control study was conducted using retrospective data (2018-2020) from PrEP users monitored by Brazil's Unified Health System (SUS) via the Medicines Logistics Control System (SICLOM). Cases (interrupted PrEP, n = 629) were matched 1:10 by sex at birth and age to controls (maintained PrEP, n = 6290). Logistic regression identified factors associated with discontinuation.

resultsFactors significantly associated with PrEP discontinuation included previous anal lesions (adjusted Odds Ratio: 1.92; 95% Confidence Interval [CI]: 1.06-3.28; p = 0.022), active infections within the first 30 days of PrEP (aOR: 1.51; 95% CI 1.07-2.07; p = 0.014), and frequent medication forgetfulness (aOR: 1.48; 95% CI 1.19-1.84; p < 0.001). Not experiencing adverse effects during the first month was protective (aOR: 0.73; 95% CI 0.61-0.87; p < 0.001). The median time until discontinuation was 8 months.

conclusionEarly clinical experiences and adherence behaviors are critical for PrEP continuation. Enhanced support and monitoring, particularly in the first 30 days post-initiation, are pivotal to improve PrEP persistence in Brazil.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisTreatment InterruptionAdultBrazilCase-Control StudiesFemaleHumansMaleMedication AdherenceAnti-HIV AgentsBrazilHIV infectionsMedication adherencePre-Exposure prophylaxis

Identifiers

PMID40841654
PMCPMC12372239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.